Shopping Cart
- Remove All
- Your shopping cart is currently empty
LQVTDSGLYRCVIYHPP (LP17) is a TREM-1 (triggering receptor expressed on myeloid cells) inhibitory peptide that mitigates ischemia-induced infarction and neuronal damage. It can penetrate the brain and inhibit TREM-1 [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $60 | 7-10 days | |
5 mg | $147 | 7-10 days | |
10 mg | $263 | 7-10 days | |
25 mg | $446 | 7-10 days | |
50 mg | $645 | 7-10 days | |
100 mg | $886 | 7-10 days | |
500 mg | $1,790 | 7-10 days |
Description | LQVTDSGLYRCVIYHPP (LP17) is a TREM-1 (triggering receptor expressed on myeloid cells) inhibitory peptide that mitigates ischemia-induced infarction and neuronal damage. It can penetrate the brain and inhibit TREM-1 [1]. |
In vitro | Treatment with LQVTDSGLYRCVIYHPP (LP17) at concentrations of 1 or 10 µM for 24 hours significantly reduced the mRNA levels of pro-inflammatory cytokines and chemokines following reoxygenation. Additionally, it notably decreased the extracellular protein levels of IL-1β and IL-18 in an oxygen-glucose deprivation (OGD) model of microglial cells [1]. At a concentration of 10 µM and the same duration, LP17 was found to interact with the SYK enzyme in microglial cells [1]. |
In vivo | LP17 (0.5 or 1 mg/kg; intranasal; once daily for 3 days) attenuated ischemia-induced infarction and neuronal damage in mice [1]. |
Molecular Weight | 1961.24 |
Formula | C89H137N23O25S |
Cas No. | 887255-16-5 |
Storage | keep away from moisture | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.